CERo Therapeutics Holdings Inc
CERO
Company Profile
Business description
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Contact
201 Haskings Way
Suite 230
South San FranciscoCA94080
USAT: +1 650 407-2376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 2.30 | 0.03% |
CAC 40 | 7,766.71 | 43.24 | 0.56% |
DAX 40 | 24,206.91 | 133.24 | 0.55% |
Dow JONES (US) | 44,280.79 | 125.57 | -0.28% |
FTSE 100 | 8,854.18 | 47.65 | 0.54% |
HKSE | 24,148.07 | 260.24 | 1.09% |
NASDAQ | 20,440.79 | 28.27 | 0.14% |
Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
S&P 500 | 6,231.57 | 1.59 | 0.03% |
S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
SSE Composite Index | 3,497.48 | 24.35 | 0.70% |